Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

NCT00590824 | Completed Phase 2 Results DMC FDA Drug

• 7 other identifiers: H-2007-0087CO056012013-1224NCI-2009-00276A536755SMPH/PEDIATRICS/PEDIATRICSR01CA032685
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluate the antitumor activity of hu14.18-IL2 in the minimal residual disease setting. Evaluate the time to recurrence and overall survival of patients treated with hu14.18-IL2.

Conditions

Melanoma

Keywords

Melanoma; hu14.18-IL2

Outcome Measures

Primary Outcomes (3)

• Ganglioside Expressed by Tumor Cells (GD2)

  Histological analysis of anti-tumor activity is a primary endpoint. This is measured after surgical resection via staining to indicate GD2 expression. The GD2 results were summarized in terms of positive (GD2 expression high or low/moderate) and negative (GD2 expression undetectable).

  up to 1 week

• Recurrence Free Survival (RFS)

  RFS was defined as the number of days from the day of evaluation following course 2 of immunocytokine treatment to the day the subject experienced an event of recurrence or death, whichever occurred first. Participants who did not experience an event of recurrence or death at the time of analysis were censored at the date of the last evaluation for recurrence.

  up to 24 months

• Overall Survival (OS)

  OS was defined as the number of days from randomization to the date of the participant's death. Participants who did not experience an event of death at the time of analysis were censored at the date of the last follow-up.

  up to 24 months

Secondary Outcomes (5)

• C-Reactive Protein (CRP)

  up to 29 days

• Lymphocyte Count

  up to 29 days

• Anti-Idiotypic Antibodies

  up to 12 weeks

• Anti-Fc-IL2 Antibodies

  up to 12 weeks

• In Vitro Soluble Interleukin-2 (IL2) Receptor Alpha Levels

  up to 12 weeks

Other Outcomes (8)

• Tumor Vascularity

  Up to 1 week

• Immunocytokine (IC) Binding

  up to 1 week

• Interferon Gamma (INF-y) Expression

  Up to 1 week

Study Arms (2)

A

EXPERIMENTAL

Hu14.18-IL2 --\>Resection--\>Hu14.18-IL2

Drug: hu14.18-IL2

B

EXPERIMENTAL

Resection --\>Hu14.18-IL2--\>Hu14.18-IL2

Drug: hu14.18-IL2

Interventions

hu14.18-IL2 DRUG

6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2

A

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must have recurrent stage III (i.e., recurrent regional metastasis), or stage IV (i.e., any distant metastasis) melanoma for which surgical resection would be clinically recommended, with biopsy proven (current or previous) Stage III or Stage IV disease. Any biopsies obtained to demonstrate recurrent regional metastasis or distant metastasis must be considered clinically appropriate for clinical management and must not be performed solely for meeting eligibility criteria. In addition, subjects must have disease that has not yet been completely excised.
• Patients must have disease which involves 3 or fewer sites. A nodal basin recurrence will be scored as one site, even if multiple nodes are positive. "Clustered" subcutaneous and/or cutaneous lesions that can be removed in a single surgical excision will be scored as one site, even if multiple subcutaneous and/or cutaneous lesions are present.
• The subjects' disease is determined to be completely resectable with uninvolved margins using standard surgical guidelines based on physical exam and radiographic imaging (MRI or CT of the head, and CT or MRI of the chest, abdomen and pelvis).
• Subjects must have one of the following: a) Stage III melanoma with recurrence after prior surgery, with or without subsequent adjuvant systemic (standard or experimental) and/or radiotherapy management Or b) Stage IV melanoma (cutaneous, ocular, mucosal, or unknown primary)
• Subjects must be 18 years old or older OR if they are 15 years old or greater, considered to be mature minors, able to give adult informed consent (with parental co-signature), meet all other eligibility criteria, and also weigh at least 45 kg.. Subjects must weigh at least 45 kg in order to safely provide sufficient blood for monitoring studies (see section 7.7 for details).
• Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Subjects must have adequate bone marrow, liver, and renal function.
• Subjects with one or more of the following cardiac risk factors must complete a stress radionuclide scan with no evidence of myocardial ischemia or heart failure: (a) a history of cardiac disease, (b) age greater than 65 years old, (c) any clinically significant abnormality found on ECG (required at baseline), or (d) significant risk factors for coronary artery disease (history of significant dyslipidemia; any treatment for dyslipidemia; or two first degree relatives with a documented myocardial infarction prior to age 55).
• Subjects with significant history of pulmonary disease, shortness of breath at rest, or known Chronic Obstructive Pulmonary Disease (COPD) must have pulmonary function tests within 35% of normal age-predicted values.
• Subjects must be willing and able to provide informed written consent prior to any study-related procedures.
• Subjects must have no immediate requirements for palliative chemotherapy, palliative radiotherapy, or palliative hormonal therapy.
• Subjects must be willing and able to discontinue antihypertensive medications if advised to do so for days of hu14.18-IL2 infusion.
• Subjects must have slides available from stage III or stage IV melanoma. Paraffin blocks are preferable, but at a minimum, slides documenting melanoma by biopsy (including fine needle cytology) must be available for pathology review, and potential restaining/staining (see Section 7.4, Surgical Pathology Guidelines). Prior histologic demonstration of metastatic melanoma (either stage III or Stage IV) may be utilized if a repeat biopsy is not clinically needed to to establish eligibility.

You may not qualify if:

• Subjects are ineligible if they have received monoclonal antibodies (mAb) during biologic therapy, tumor imaging, purging of autologous marrow/stem cells for re-infusion or for any other reason unless serological testing is performed. If the absence of detectable antibody (over background) to hu14.18 is documented, the subject is eligible for the study.
• Subjects treated with IL2 in the past that developed intolerable (Grade 4) IL2-related side effects are not eligible.
• Subjects who have received any (standard or experimental) systemic therapy for stage IV disease are not eligible.
• Women of childbearing potential will be excluded if they are pregnant, nursing, or not using effective contraception during the treatment period.
• Subjects with symptoms of ischemic cardiac disease, congestive heart failure, myocardial infarct within the immediate preceding 6 months and/or uncontrolled cardiac rhythm disturbance are ineligible.
• Subjects with significant psychiatric disabilities or seizure disorders are ineligible.
• Subjects who have had major surgery within the past 3 weeks are ineligible.
• Subjects with clinically detectable pleural effusions or ascites are ineligible.
• Subjects with organ allografts are ineligible.
• Subjects who require or are likely to require corticosteroid or other immunosuppressive drugs or have used them within 2 weeks of registration are ineligible.
• Subjects with significant intercurrent illnesses are ineligible.
• Subjects with active infections or active peptic ulcer unless these conditions are corrected or controlled are ineligible.
• Subjects with brain metastases, whether active or inactive, are ineligible. A head MRI or head CT scan will be required at baseline to rule out silent metastases.
• Subjects with active second malignancy other than non-melanoma skin cancer are ineligible. Patients will be considered eligible if they have been continuously disease free for \> 5 years prior to the time of enrollment.
• Subjects who are infected with human immunodeficiency virus (HIV), hepatitis B surface antigen (HBs Ag) carrier state or with clinical evidence of hepatitis are ineligible. Treatment may be initiated before laboratory confirmation of HIV and HBs Ag negativity, but will be stopped if results are positive.

Sponsors & Collaborators

• University of Wisconsin, Madison: lead
• National Cancer Institute (NCI): collaborator
• EMD Serono: collaborator

Study Sites (1)

University of Wisconsin Hospitals and Clinics

Madison, Wisconsin, 53792, United States

Location

Related Publications (2)

• Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, Kim K, Loibner H, Gillies SD, Sondel PM. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother. 2018 Oct;67(10):1647-1658. doi: 10.1007/s00262-018-2223-z. Epub 2018 Aug 3.

  PMID: 30073390 RESULT

• Yang RK, Kuznetsov IB, Ranheim EA, Wei JS, Sindiri S, Gryder BE, Gangalapudi V, Song YK, Patel V, Hank JA, Zuleger C, Erbe AK, Morris ZS, Quale R, Kim K, Albertini MR, Khan J, Sondel PM. Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. Clin Cancer Res. 2020 Jul 1;26(13):3296-3306. doi: 10.1158/1078-0432.CCR-19-3294. Epub 2020 Mar 9.

  PMID: 32152202 DERIVED

Related Links

• University of Wisconsin Carbone Cancer Center

MeSH Terms

Conditions

Melanoma

Interventions

lorukafusp alfa

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Results Point of Contact

• Title: Paul Sondel, MD, PhD
• Organization: University of Madison Carbone Cancer Center

pmsondel@humonc.wisc.edu

(608) 263-9069

Study Officials

• Paul M Sondel, MD, PhD

  University of Wisconsin, Madison

  PRINCIPAL INVESTIGATOR

• Mark R Albertini, MD

  University of Wisconsin, Madison

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 19, 2007
• First Posted: January 11, 2008
• Study Start: December 17, 2007
• Primary Completion: September 20, 2018
• Study Completion: September 20, 2018
• Last Updated: November 21, 2019
• Results First Posted: October 22, 2019

Record last verified: 2019-11

Locations

US (1)